Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

ACS CAN provided comments on recent draft guidance issued by FDA intended to improve diversity of clinical trial participants.  Our comments built on recent consensus recommendation issued last year. 

The Henrietta Lacks Enhancing Cancer Research Act of 2019 directs GAO to evaluate federal policies and programs for their impact on enrollment in cancer clinical trials, with a focus on how underserved trial enrollment is impacted.  This letter expresses the support of over two dozen organization

ACS CAN responded to the reopening of the Centers for Medicare and Medicaid Services (CMS) coverage decision for NGS testing panels.  ACS CAN comments stressed that the existing coverage framework improperly freezes coverage based on current science rather than allowing a framework that could evo

Restrictive eligibility criteria are the second leading cause preventing patients from enrolling in cancer clinical trials.  FDA recently issued draft guidance encouraging trial sponsors to use a science-based approach that would allow a wider variety of patients to participate in cancer clinical

Over 80 organizations are urging Congress to take up and pass reform to modernize the oversight of diagnostic test. 

Biomarker testing is critical to successfully realizing personalized medicine, both through the selection of appropriate targeted therapies as well as by directing patients to relevant clinical trials.  This report examines the private payer landscape of coverage for tumor biomarker tests in lung

Cancer registries provide high quality cancer data to inform policy at the local, state, and national levels. That National Program of Cancer Registries (NPCR) provides technical, operational, and financial support to most state cancer registries to help ensure data collected is representative of the U.S. population.

This bill would modernize and harmonize oversight of in-vitro diagnostic tests, and ACS CAN provided feedback to draft legislative language.  The feedback addressed core issues of interest to patients.

Over 50 individuals convened over the course of two days to develop recommendations that would improve the ability of patient-facing cancer clinical trial matching services to help patients find suitable clinical trials.  The summit resulted in nine consensus recommendations focused on improving